Jerome Moreaux
Co-founder of Diag2tec Company at Diag2tec
Based in Montpellier, France
7-day free trial · no credit card
Seniority
C-Team
Department
Other
Location
Montpellier
Industry
Biotechnology Research
Company size
11
Contact information
Reveal Jerome's email and phone
Direct contact data is gated. Sign up and reveal. You only pay for verified records.
j•••••••@diag2tec.com
Phone
5 credits+33 ••• •••• ••••
You only pay for valid records. Bounced emails and disconnected numbers cost nothing.
Background
About Jerome Moreaux
MOREAUX Jérôme, Age: : PhD in Biological Sciences, UM I2011: Accreditation to supervise research. UM II (HDR)2013: University degree: Pedagogy of medical education.UM IProfessional qualifications2014-2022 : Associate Professor, CNU 87, Faculty of Medicine. UM.2018 : Junior Member at Institut Universitaire de France (IUF)2022-present : Professor, CNU87, Faculty of Medicine. UM.Professional activity2015: Co-founder of Diag2Tec : Head of Laboratory for Monitoring Innovative Therapies. University Hospital of Montpellier.2020-present : Team Labelized Institut Carnot du Lymphome (CALYM),(https://experts-recherche-lymphome.org/calym/parcourir-les-entites-membres/).2021-present : PI team Epigenome modifications and genomic instability in normal and malignant B cells. IGH Montpellier.Main Awards, Honors and Main Grants-"Chercheur d'avenir" Languedoc Roussillon Region Grant: 2014-2016- Fondation de France: 2014-2016- FFRMG Grant: 2014-2016- Ilab Award (Diag2Tec)(2016)- Epigenetic and Cancer; MM: Epigenetic Mining and Therapeutic Targeting; 2015-2018- INCA PLBIO 2015 Grant; 2015-2018- K2 prize Cancerology 2017- ANR Tie-SKIP; 2017-2020- ARC subvention; 2018-2021- INCA PLBIO 2018; PIT_MM; 2018-2021- ANR 2018; 2018-2021- Companies on Campus. MUSE Université Montpellier; 2019-2021- INCA PLBIO 2019-2022- ITMO PCSI 2020 - ARC PGA 2022 2022-2025- AAP ECOPHYTO - PELYCANO 2022-2025- HORIZON-MISS-2021-CANCER-02 - 2023-2027.Scientific Production:120 publications. 4 book chapters. 19 patents. Hirsh factor: 38.Patents: 1- Patent n° 10305892, 2010.2- Patent EP12306141.8, 2012.3- Patent EP12306225.9, 2012.4- Patent EP14305404, 2014.5- Patent EP14306201. 2014.6- Patent EP16305176. 2016.7- Patent EP16305682. 2016.8- Patent FR1654514. 2016.9- Patent EP16305651. 2016.10- Patent EP16306436.3. 201611- Patent EP17306503.8. 2017.12- Patent BR76264. 2017.Reviewing activity:Reviewer for national (Ligue Contre le Cancer, SIRIC, AFMF, FFRMG, IDEX, ARSEP, ECOS-Sud and international (Kom Op Tegen Kanker, Fonds Wetenschappelijk Onderzoek, British Skin Foundation, Bloodwise, KWF (Dutch Cancer Society), NOW (Dutch Research Council), Swiss SNF, American Society of Hematology, ERC starting grants) agencies.Clinical trial:Clinical trial evaluating the interest of the GEP-based derived “histone acetylation” score to identify myeloma patients who could benefit from treatment with HDAC inhibitor. J Moreaux.
Decision-makers
Other people at Diag2tec
Build a list of verified contacts at Diag2tec
Free for 7 days · 50 credits · no card · only pay for verified records.
Reach more buyers like Jerome
250M+ professionals with verified email and phone. You only pay for records that actually verify.
7-day trial · no credit card · cancel anytime